FDA Approves Garadacimab-gxii in Hereditary Angioedema
Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.
Related Articles
Long-Acting HIV Therapies: Real-World Data and Clinical Application
A panelist discusses how the injectable combination of cabotegravir and rilpivirine performed well in the real-world OPERA cohort, with over 95% of patients maintaining virologic…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
LISTEN TO THE EXPERTS
Sponsored by Novartis US Medical Affairs Elevated lipoprotein(a) (Lp[a]) represents the most common type of genetic dyslipidemia. 1 Elevated Lp(a) levels occurring in 20% of…
Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Unaddressed Adverse Effects Undermine Patient Confidence in Lymphoma, CLL Care Plans: Lorna Warwick
Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of…
American Journal of Managed Care News & Expert Insights | AJMC
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.